PCSK9 inhibitors for LDL lowering

  • Walsh J
  • 12


    Mendeley users who have this article in their library.
  • 1


    Citations of this article.


A review. In this issue of Trends in Cardiovascular Medicine, Desai and Sabatine thoroughly review recent and ongoing trials of three monoclonal antibodies that disrupt PSCK9 binding to LDLreceptors,leading to marked redns. in LDL-C. As detailed in their review, evolocumab(AMG145), alirocumab(SAR236553/REGN727), and bococizumab(RN316) given every 2-4 wk, reduced LDL-C up to 75% in patients on statin therapy as compared to statin therapy alone, up to 51% in statin-intolerant patients and other patients not in statin therapy, and up to 55% in patients with heterozygous familial hypercholesterolemia, most of whom were on statin therapy. [on SciFinder(R)]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • James P. Walsh

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free